The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner
Kirollos Hanna,(1) PharmD, BCPS, BCOP, and Kelley Mayden,(2) MSN, FNP, AOCNP®
From (1)Mayo Clinic and M Health Fairview, Rochester, Minnesota; (2)Ballad Health Cancer Care-Bristol, Bristol, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Kirollos Hanna, PharmD, BCPS, BCOP, 200 First St. SW, Rochester, MN 55905. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2021;12(suppl 2):3–5 |
© 2021 Harborside™
Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancer-related death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017.
For access to the full length article, please sign in